TWTifenn Wauquier

Tifenn Wauquier

*This is an algorithmically generated author record based on publicly available information.

Tifenn Wauquier has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    The STING HAQ haplotype and clinical non-penetrance in COPA syndrome

    by Clémence David, Tifenn Wauquier, Alix de Becdelièvre, Camille Louvrier, Maud Tusseau, Cécile Masson, Luis Seabra, Caroline Kannengiesser, Hayssam Al Arab, Ibrahima Ba, et al.

    COPA syndrome is a rare monogenic autoinflammatory disease due to heterozygous mutations in COPA, encoding the coatomer subunit α. COPA syndrome demonstrates phenotypic overlap with STING-associated vasculopathy with onset in infancy (SAVI), the latter due to gain-of-function mutations in STING1. Indeed, STING activation is a key driver of the pathogenesis of COPA syndrome, and a recent report suggested that the presence of the common HAQ STING allele confers complete protection against the development of clinical disease in the context of pathogenic heterozygous mutations in COPA. Given the potential significance of this result for patient management, we investigated the STING HAQ haplotype status of a separate cohort of individuals segregating pathogenic mutations in COPA. In doing so, we ascertained five HAQ-negative, clinically asymptomatic individuals aged 30, 39, 39, 42, and 43 years at last evaluation, and an HAQ-positive male with kidney disease that we consider most likely attributable to the recurrent R233H mutation in COPA. Our findings challenge the suggestion that STING haplotype status is the sole determinant of clinical penetrance in COPA syndrome.


  • Open Access

    Spondyloenchondrodysplasia: An enigmatic immuno-osseus type I interferonopathy

    by Callie C.Y. Wong, Tifenn Wauquier, Carolina Uggenti, Colin Stok, Alice Lepelley, Marie-Louise Frémond, Yanick J. Crow

    Spondyloenchondrodysplasia (SPENCD) is a rare immuno-osseus disease due to biallelic mutations in ACP5, resulting in a loss of tartrate-resistant acid phosphatase (TRAP) activity and enhanced type I interferon signalling. While TRAP was identified in the 1950s, ACP5 was cloned in the 1990s, an Acp5 knockout mouse was reported in 1996, and >3,000 articles are retrievable on PubMed using the terms “tartrate-resistant acid phosphatase” + “TRAP”, the immunopathology of SPENCD remains unclear. Here we describe the clinical phenotype and molecular architecture of SPENCD, review the biology of TRAP, and consider how TRAP deficiency leads to disturbed innate immunity.